We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intersect ENT (XENT) SINUVA Implant Receives FDA Approval
Read MoreHide Full Article
Intersect ENT, Inc. received approval from the FDA for SINUVA Sinus Implant. The company has been focused on developing innovative therapies for chronic sinusitis patients.
SINUVA is an exclusive approach to treat recurrent nasal polyp disease in patients who have undergone ethmoid sinus surgery. Per management, approximately 635,000 Americans have gone through these surgeries and are looking for treatments to cure side effects.
Intersect ENT expects SINUVA to be costlier than other products in the portfolio. However, higher price will not dent the company’s gross margins in the upcoming fourth quarter. It has a long-term expected earnings growth rate of 25%.
Notably, nasal polyps are inflammations along the lining of nasal passage or sinus resulting in congestion, infections and low sense of smell. SINUVA is Intersect ENT’s fourth commercial product, which is likely to be introduced to physicians across the country in the following months.
Shares Shine Bright
Year to date, Intersect ENT has had a solid run on the bourses, trading above the market at large. The company returned 163.2% comparing favorably with the industry’s rally of only 23.2%. Also, the current return is higher than the S&P 500 index’s increase of 21.7% over the same time frame. The stock has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Market Trends Buoy Optimism
Introduction of new technologies and rapid innovations in healthcare market are creating opportunities for companies that are striving to make profits in the sinusitis treatment market. Per a report by Persistence Market Research, the Center of Disease Control and Prevention (CDC) has revealed that 11.7 million people in the United States get diagnosed with chronic sinusitis on a regular basis.
Considering the solid prospects of the market, we believe that Intersect ENT will gain strong market traction in the upcoming days. A few other major market players engaged in the manufacturing of treatment products for sinusitis include Sanofi (SNY - Free Report) , Abbott Laboratories (ABT - Free Report) and Eli Lilly And Company (LLY - Free Report) .
Our Take
Intersect ENT’s fourth-quarter operating expenses are likely to rise, thanks to the one-time expenses related to the SINUVA launch, production of demo units and costs related to market-access infrastructure.
Among latest developments, PROPEL Contour is expected to be an important driver for Intersect ENT. Products like PROPEL and PROPEL mini are drug-eluting implants for patients suffering from chronic sinusitis. It offers products and therapies for ear, nose and throat surgeons to improve treatment of patients with chronic diseases.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Intersect ENT (XENT) SINUVA Implant Receives FDA Approval
Intersect ENT, Inc. received approval from the FDA for SINUVA Sinus Implant. The company has been focused on developing innovative therapies for chronic sinusitis patients.
SINUVA is an exclusive approach to treat recurrent nasal polyp disease in patients who have undergone ethmoid sinus surgery. Per management, approximately 635,000 Americans have gone through these surgeries and are looking for treatments to cure side effects.
Intersect ENT expects SINUVA to be costlier than other products in the portfolio. However, higher price will not dent the company’s gross margins in the upcoming fourth quarter. It has a long-term expected earnings growth rate of 25%.
Notably, nasal polyps are inflammations along the lining of nasal passage or sinus resulting in congestion, infections and low sense of smell. SINUVA is Intersect ENT’s fourth commercial product, which is likely to be introduced to physicians across the country in the following months.
Shares Shine Bright
Year to date, Intersect ENT has had a solid run on the bourses, trading above the market at large. The company returned 163.2% comparing favorably with the industry’s rally of only 23.2%. Also, the current return is higher than the S&P 500 index’s increase of 21.7% over the same time frame. The stock has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Market Trends Buoy Optimism
Introduction of new technologies and rapid innovations in healthcare market are creating opportunities for companies that are striving to make profits in the sinusitis treatment market. Per a report by Persistence Market Research, the Center of Disease Control and Prevention (CDC) has revealed that 11.7 million people in the United States get diagnosed with chronic sinusitis on a regular basis.
Considering the solid prospects of the market, we believe that Intersect ENT will gain strong market traction in the upcoming days. A few other major market players engaged in the manufacturing of treatment products for sinusitis include Sanofi (SNY - Free Report) , Abbott Laboratories (ABT - Free Report) and Eli Lilly And Company (LLY - Free Report) .
Our Take
Intersect ENT’s fourth-quarter operating expenses are likely to rise, thanks to the one-time expenses related to the SINUVA launch, production of demo units and costs related to market-access infrastructure.
Among latest developments, PROPEL Contour is expected to be an important driver for Intersect ENT. Products like PROPEL and PROPEL mini are drug-eluting implants for patients suffering from chronic sinusitis. It offers products and therapies for ear, nose and throat surgeons to improve treatment of patients with chronic diseases.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>